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exome sequencing yielded rare, simultaneously heterozygous variants in the Aicardi-
Goutières syndrome (AGS) genes ADAR and RNASEH2B co-segregating with the
tumor phenotype. AGS is a genetically induced inflammatory disease particularly of the
brain, which has not been associated with a consistently increased cancer risk to date.
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to 17-fold frequency increase of the AGS mutations ADAR,c.577C>G;p.(P193A) and
RNASEH2B,c.529G>A;p.(A177T) in the germline of familial glioma patients as well as
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ethnicity-matched controls, whereby rare RNASEH2B variants were significantly more
frequent in familial glioma patients. Tumors with ADAR or RNASEH2B variants
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interferon-stimulated gene (ISG) transcripts in peripheral blood as seen in AGS. An
increased ISG expression was also induced by ADAR and RNASEH2B variants in
tumor cells and was blocked by the JAK inhibitor Ruxolitinib. Our data implicate rare
variants in the AGS genes ADAR and RNASEH2B and a type I interferon signature in
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underlying inflammation-driven malignant transformation in glioma and prostate
carcinoma development.
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Abstract 
In search of novel germline alterations predisposing to tumors, in particular to gliomas, we 
studied a family with two brothers affected by anaplastic gliomas, and their father and paternal 
great-uncle diagnosed with prostate carcinoma. In this family, whole-exome sequencing yielded 
rare, simultaneously heterozygous variants in the Aicardi-Goutières syndrome (AGS) genes 
ADAR and RNASEH2B co-segregating with the tumor phenotype. AGS is a genetically induced 
inflammatory disease particularly of the brain, which has not been associated with a consistently 
increased cancer risk to date. By targeted sequencing, we identified novel ADAR and 
RNASEH2B variants, and a 3- to 17-fold frequency increase of the AGS mutations 
ADAR,c.577C>G;p.(P193A) and RNASEH2B,c.529G>A;p.(A177T) in the germline of familial 
glioma patients as well as in test and validation cohorts of glioblastomas and prostate carcinomas 
versus ethnicity-matched controls, whereby rare RNASEH2B variants were significantly more 
frequent in familial glioma patients. Tumors with ADAR or RNASEH2B variants recapitulated 
features of AGS, such as calcification and increased type I interferon expression. Patients 
carrying ADAR or RNASEH2B variants showed upregulation of interferon-stimulated gene (ISG) 
transcripts in peripheral blood as seen in AGS. An increased ISG expression was also induced by 
ADAR and RNASEH2B variants in tumor cells and was blocked by the JAK inhibitor Ruxolitinib. 
Our data implicate rare variants in the AGS genes ADAR and RNASEH2B and a type I interferon 
signature in glioma and prostate carcinoma risk and tumorigenesis, consistent with a genetic 
basis underlying inflammation-driven malignant transformation in glioma and prostate carcinoma 
development. 
 
Keywords 
Whole-exome sequencing; Aicardi-Goutières syndrome; glioma; prostate carcinoma; type I 
interferon signaling 
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Introduction 
Diffuse gliomas are brain tumors classified by the World Health Organisation (WHO) according to 
their malignancy, encompassing astrocytomas and oligodendrogliomas of grade II or III, and 
glioblastomas classified as most malignant grade IV. Most cases of diffuse glioma, as well as of 
prostate carcinoma occur sporadically. However, familial aggregation of gliomas does exist, 
accounting for around 5% of patients according to Malmer et al. [43]. Also, glioma susceptibility is 
increased in patients suffering from certain inherited cancer syndromes, such as 
neurofibromatosis type 1 and 2, Li-Fraumeni syndrome, and brain tumor polyposis syndromes 1 
(Turcot) and 2 (Gardner) (reviewed in [36]), suggesting that genetic alterations play a role in 
glioma risk. Similarly, familial prostate cancer has been described and tumor syndromes exist 
that are associated with prostate cancer susceptibility, e.g. Lynch syndrome and hereditary 
breast and ovarian cancer caused by mutations in DNA-repair genes (reviewed in [41]). 
Interestingly, genetic alterations in certain genes (e.g. the mismatch repair genes MSH2, MSH6, 
MLH1, and PMS2) or chromosomal regions (e.g. the 8q24 locus) confer increased risk for 
different tumor entities including gliomas [35, 36] and prostate cancer [4, 41]. Therefore in some 
families, gliomas and prostate cancer may both be part of a tumor spectrum associated with a 
common genetic basis. Screening these families for tumor predisposing germline alterations may 
allow identification of novel genes increasing the risk for these tumor entities, which may also be 
relevant for sporadic tumor patients. As next generation sequencing technologies have been 
instrumental in identifying new tumor predisposing genes, such as POT1 [5] in familial gliomas, 
we performed whole-exome sequencing in a family with gliomas and prostate carcinomas in four 
individuals from three consecutive generations. In all affected individuals analyzed, an 
overlapping data analysis strategy yielded rare, simultaneously heterozygous variants in ADAR 
and RNASEH2B, two genes mutated in Aicardi-Goutières syndrome (AGS). 
 AGS was first described as an infancy onset and rapidly progressive encephalopathy with 
basal ganglia calcifications and lymphocytosis in the cerebrospinal fluid, reminiscent of an 
inflammatory process [2]. Presently, AGS is known to be a genetic disorder inherited in an 
autosomal recessive manner in most cases, and is referred to as a type I interferonopathy 
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because of a constitutive upregulation of type I interferon (IFN) signaling (reviewed in [18]). The 
genetic cause of AGS is a mutation in one of seven genes, which encode the three subunits of 
the ribonuclease H2 (RNase H2) endonuclease complex, RNASEH2A, RNASEH2B and 
RNASEH2C [17], the 3’-5’ DNA exonuclease TREX1 [16], the deoxynucleoside triphosphate 
triphosphohydrolase and putative exonuclease SAMHD1 [58], the adenosine deaminase acting 
on RNA ADAR [60], or the cytosolic double-stranded RNA (dsRNA) receptor IFIH1 [59]. ADAR is 
a dsRNA-editing enzyme that catalyzes the conversion of adenosine to inosine mainly in 
transcripts expressed in the central nervous system (CNS) [32], and it is an essential suppressor 
of interferon signaling [27]. RNase H2 cleaves the RNA strand of cellular RNA:DNA hybrids and 
hydrolyzes ribonucleotides misincorporated into DNA (reviewed in [55]). It is essential for genome 
stability and mouse embryonic development, with wide-spread DNA damage observed in RNase 
H2 null cells [30, 56]. RNase H2 deficiency is thought to cause accumulation of cytoplasmic DNA 
or RNA:DNA resulting from genome instability or endogenous retroviruses, which activate the 
cGAS-STING innate immune pathway [42, 53]. 
 More generally, accumulation of unprocessed self nucleic acids and subsequent activation of 
type I IFN signaling are thought to underlie AGS disease pathogenesis. Clinical features include 
an IFN-stimulated gene (ISG) expression signature as well as inflammation, calcification and 
neurodegeneration (reviewed in [31]). However, there have also been suggestions that AGS 
gene variation may be associated with tumorigenesis. Altered ADAR-mediated A-to-I RNA editing 
was detected in human cancer, whereby global hypoediting described in brain and prostate 
tumors [50] may be involved in the dedifferentiation of glioma cells [34]. Loss of RNase H2 
function was shown to lead to large-scale genomic instability [56], which may be relevant for 
tumorigenesis. More evidence for an association of AGS and tumor risk comes from an AGS 
patient carrying a SAMHD1 germline mutation who developed chronic lymphocytic leukemia 
(CLL) at 24 years of age [14]. Additionally, somatic SAMHD1 variants were found in around 10% 
of relapsed or refractory patients with CLL [14]. 
 In the present study, we present data suggesting that rare partial loss-of-function variants 
affecting AGS-associated genes ADAR and RNASEH2B increase the risk for glioma and prostate 
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carcinoma. Glioma patients carrying ADAR and/or RNASEH2B mutations and their tumors show 
signs of a type I interferonopathy. In summary, our data suggest a genetic link between 
inflammatory processes and the development of glioma and prostate carcinoma. 
 
 
Materials and methods 
Human samples 
For the familial glioma cohort (n=60, of these 33 patients were diagnosed with glioblastoma of 
WHO grade IV), blood samples were collected from glioma patients with evidence for a genetic 
tumor predisposition because of multiple successive tumors in the glioma patient or tumors in the 
family history, mainly in Hannover, Lower Saxony, Germany. This cohort includes families 1 and 
2. From patient II.2 of family 2, a skin biopsy was performed to obtain fibroblasts. Control 
fibroblasts were derived from four sex-matched individuals. For the non-familial glioma cohort 
(n=50, of these 41 patients were diagnosed with glioblastoma), blood samples were collected 
from glioma patients without multiple successive tumors or family history of tumors in Hannover, 
Germany. Blood samples from 130 glioma patients diagnosed with IDH1-mutant gliomas of WHO 
grades II or III had been collected in multiple German centers excluding Hannover, and were 
retrieved from the archives of the German Glioma Network (GGN) (www.gliomnetzwerk.de) [54, 
65], which was supported by the German Cancer Aid from 2004 to 2012. Formalin-fixed paraffin-
embedded (FFPE) samples from 39 gliomas of WHO grades II or III shown to be IDH1-mutant 
and from 20 glioblastomas (test cohort) were retrieved from the archives of the Department of 
Neuropathology, Hannover Medical School, Hannover, Germany. The glioblastoma test cohort 
includes patient II.1 of family 3, whose RNASEH2B variant was also detected in non-neoplastic 
tissue representing the germline. DNA from 56 glioblastomas (validation cohort) was retrieved 
from the GGN archives. DNA from 15 FFPE prostate carcinoma samples (test cohort) was 
retrieved from the archives of the Institute of Pathology, Hannover Medical School, Hannover, 
Germany. The prostate carcinoma test cohort includes patients II.1 of families 4 and 5, whose 
ADAR or RNASEH2B variants were also detected in non-neoplastic lymph node representing the 
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germline. FFPE samples from 50 prostate carcinomas (validation cohort) were retrieved from the 
archives of the Institute of Pathology, University of Rostock, Rostock, Mecklenburg-Western 
Pomerania, Germany. All patients provided written informed consent for the use of their tissue 
samples for research purposes. The study was approved by the Ethics Board of Hannover 
Medical School, Hannover, Germany, and of the University of Tübingen, Germany. 
 
Whole-exome sequencing (WES) 
WES on whole blood DNA from three cancer-affected members of family 1 (patients II.2, III.2, 
and III.3), and on tumor DNA from the anaplastic glioma of patient III.3 of family 1 was done using 
the Agilent SureSelectXT All Exon V4 (blood and tumor DNA from patients III.2 and III.3) or V5 
(blood DNA from patient II.2) target enrichment kits on an Illumina HiSeq 2000 by Oxford Gene 
Technology (OGT) [13]. All samples were sequenced to a mean target coverage of >50x. More 
specifically, on whole blood DNA from patients II.2, III.2, and III.3, average coverage of the ADAR 
coding region was 62x, 96x, and 79x whereby 91%, 88%, and 86% were covered at >25x, while 
average coverage of the RNASEH2B coding region was 60x, 52x, and 39x whereby 77%, 82%, 
and 66% were covered at >25x. WES germline data were analyzed using INGENUITY Variant 
AnalysisTM (INGENUITY Systems, QIAGEN, Redwood City, USA) and our in-house NGS data 
analysis workflow as described in Results and Supplementary Tables 1-4. For prediction of 
variant deleteriousness, the tools SIFT (http://sift.jcvi.org/), PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/), MutationTaster (http://www.mutationtaster.org), and 
PROVEAN (http://provean.jcvi.org) were used. Minor allele frequency (MAF) in the European 
population (non-Finnish) were retrieved from the Exome Aggregation Consortium (ExAC) 
Browser Beta [39]. Variant verification and co-segregation analysis in families 1 and 2 was done 
using conventional chain termination protocols on a 3130XL Genetic Analyzer (Applied 
Biosystems, Darmstadt, Germany). Nucleotide numbering of the identified variants reflects 
complementary DNA (cDNA) numbering in the GenBank reference sequence. WES tumor data of 
patient III.3 of family 1 were analyzed with respect to single nucleotide variants and copy number 
variants within the ADAR and RNASEH2B loci. 
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Sequence analysis of ADAR, RNASEH2B, and SNP rs498872 at 11q23 
Whole blood genomic DNA was isolated using QIAamp blood DNA kits (Qiagen, Hilden, 
Germany). Phenol-chloroform extraction was used to isolate tumor DNA from FFPE tissue. 
Coding sequences of interferon-induced ADAR isoform p150 (NG_011844, NM_001111) or 
RNASEH2B (NG_009055, NM_024570) were amplified using oligonucleotides binding to 
sequences in close proximity to exon-intron boundaries (Supplementary Tables 5, 6). Using 
conventional chain termination protocols on a 3130XL Genetic Analyzer, (i) the entire coding 
regions including splice sites of ADAR and RNASEH2B were screened for germline mutations in 
familial glioma patients and patients with IDH1-mutant WHO grade II/III gliomas, (ii) the entire 
coding region including splice sites of RNASEH2B as well as ADAR exons 2, 5, 8 and 11 were 
screened for somatic mutations in IDH1-mutant gliomas of WHO grade II/III and the glioblastoma 
and prostate carcinoma test cohort, (iii) hot spot exons, i.e. ADAR: exons 2, 5, 8 and 11; 
RNASEH2B: exons 6 and 7, were screened for germline mutations in non-familial glioma 
patients, and for somatic mutations in the glioblastoma and prostate carcinoma validation 
cohorts. Genotyping of SNP rs498872 (NM_015157.3:c.-199A>G) located in the 5’ UTR of the 
PHLDB1 gene at 11q23 was done on germline DNA from patients II.2, III.2, and III.3 of family 1, 
and patient II.2 of family 2 using conventional chain termination protocols. 
 
Molecular characterization of gliomas  
To determine the IDH1 mutational status, tumor DNA was analyzed using Sanger sequencing or 
pyrosequencing, or immunohistochemistry using an antibody specifically recognizing the IDH1-
R132H mutation was performed on tissue sections [9, 21, 26]. O6-methylguanine DNA 
methyltransferase (MGMT) promoter methylation was assessed by methylation-specific 
polymerase chain reaction or pyrosequencing on glioma DNA [20]. The presence or absence of 
1p/19q co-deletion was determined by fluorescence in situ hybridization using 1p and 19q 
specific probes on tissue sections or array-CGH of glioma DNA.  
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Molecular dynamics (MD) simulations  
All MD simulations were carried out using NAMD 2.11 [52] and the CHARMM36 force field [7, 
25]. Starting coordinates for the duplex Z-DNA-ADAR Zα complex were taken from the crystal 
structure of human Zα domain with bound Z-DNA (PDB code: 1QBJ). Simulations were 
performed in explicit solvent using the TIP3P water model [37], and the total charge of each 
system was neutralized by adding Na+ counter ions. Each system was initially energy-minimized 
and subsequently equilibrated for at least 5 ns. MD production runs of each system were 
conducted for 100 ns at the Computer Cluster of the Norddeutscher Verbund für Hoch- und 
Höchstleistungsrechnen with periodic boundary conditions in the NpT ensemble at a constant 
temperature (310 K) and constant pressure (1 atm). A 12 Å cutoff was used for nonbonded short-
range interactions and the particle-mesh Ewald method [19] for long-range electrostatics. 
 
Cloning of expression constructs 
Human expression constructs pCMV-HA-ADAR p150 (Yanick Crow, University of Manchester, 
U.K.) and pcDNA3.1-RNASEH2B-Myc/His were described elsewhere [17, 60]. Their ORFs were 
subcloned into pIRESneo (Matthias Dobbelstein, University of Göttingen, Germany). Murine 
Rnaseh2b ORF was subcloned into pcDNA3.1-Myc vector (Thermo Fisher Scientific, Waltham, 
MA, U.S.A.). Resulting constructs were used to insert mutations: ADAR c.577C>G, RNASEH2B 
c.495G>T or c.529G>A, and Rnaseh2b c.486G>T or c.520G>A using the Phusion Site-Directed 
Mutagenesis® Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. The 
sequence of all constructs was verified using Sanger sequencing. Oligonucleotide sequences are 
shown in Supplementary Tables 7, 8. 
 
Cell culture, transfection and stimulation 
LN-229, Rnaseh2b-/-;Tp53-/- mouse embryonic fibroblasts (MEFs) [56], and skin biopsy derived 
primary human fibroblasts were cultured in DMEM (Merck Millipore, Billerica, MA, U.S.A.) 
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 1% penicillin/streptomycin 
(all Thermo Fisher Scientific). For HCT116 cells, RPMI 1640 (Merck Millipore) was used. 
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Transient transfection was done using Lipofectamine 3000 reagent (Thermo Fisher Scientific). 
Stably transfected cell lines were generated by incubation in growth medium supplemented with 
600 µg/ml geneticin (Thermo Fisher Scientific) for at least 20 days. Stable ADAR expression was 
verified by PCR amplification of ADAR wildtype/mutant inserts using oligonucleotides specifically 
binding to ADAR cDNA sequences. To inhibit JAK1/2 kinases and subsequent JAK/STAT 
signaling, LN-229 cells were treated with 1 µM of the JAK inhibitor Ruxolitinib dissolved in DMSO 
versus DMSO control (Selleck Chemicals, Suffolk, UK) for 44h. 
 
Cell proliferation assay 
Stably transfected LN-229 or HCT116 cells were seeded in triplicate at a density of 100,000 or 
150,000 cells. Cells were counted 9-12 times using the ScepterTM counter (Merck Millipore), and 
were re-seeded after counting. Growth kinetics were determined for 27 or 28 days, and specific 
growth rates were calculated. The experiment was repeated once.  
 
Detection of ribonucleotides in genomic DNA 
Rnaseh2b+/+;Tp53-/-, Rnaseh2b+/-;Tp53-/-, and Rnaseh2b-/-;Tp53-/- MEFs [56] were transiently 
transfected with Rnaseh2b constructs or empty vector and cultured for 48h. MEFs were 
mechanically disrupted in ice-cold lysis buffer (20 mM Tris-HCl, pH 7.5, 75 mM NaCl, 50 mM 
EDTA), incubated with 100 µg/ml proteinase K, and completely lysed using sodium dodecyl 
sulphate at a final concentration of 1%. Nucleic acids were sequentially extracted with TE-
equilibrated phenol, phenol:chloroform:isoamylalcohol (25:24:1), and chloroform, precipitated with 
isopropanol, washed with 75% ethanol, and dissolved in water over night at 4°C. Digestion with 
RNase HII (NEB, Frankfurt am Main, Germany) was carried out for 1h at 37°C, and nucleic acids 
were ethanol precipitated and dissolved in water. For alkaline gel electrophoresis [48], one 
volume of loading buffer (300 mM NaOH, 6 mM EDTA, 7.5% Ficoll (Type 400), 0.35% Orange G) 
was added to each sample, and DNA was separated on a 0.5% agarose gel (50 mM NaCl, 1mM 
EDTA) using an alkaline running buffer (50 mM NaOH, 1 mM NaCl) for 16h at 16V (B1 mini-gel 
format; Thermo Fisher Scientific). After electrophoresis, gels were neutralized with 0.7 M Tris/HCl 
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buffer (pH 8.0) containing 1.5 M NaCl for 1h at RT and stained with SYBR Gold for 1h at RT 
(1:10,000 dilution; Thermo Fisher Scientific). 
 
Immunofluorescence staining 
Rnaseh2b-/-;Tp53-/- MEFs transiently transfected with myc-tagged Rnaseh2b constructs or vector 
control expressing RFP, and fibroblasts from patient II.2 of family 2 and controls were fixed with 
4% paraformaldehyde, permeabilized with 0.25% Triton X-100, and probed with rabbit anti-
phospho-Histone H2AX Ser139 (1:400, #2577, Cell Signaling Technologies, Danvers, MA, 
U.S.A.). The secondary goat anti-rabbit antibody was Alexa Fluor 488-conjugated (1:500 dilution, 
A11034, Thermo Fisher Scientific). Transfected MEFs were visualized by co-immunostaining 
using mouse anti-myc (1:200 dilution, sc-40, Santa Cruz Biotechnology, Dallas, TX, U.S.A.) and 
Alexa Fluor 568-conjugated goat anti-mouse antibody (1:500 dilution, A10037, Thermo Fisher 
Scientific). Vector control transfected cells were detected by RFP fluorescence. Cell nuclei were 
counterstained with DAPI, and analyzed using an epifluorescence microscope (CW4000, Leica 
Microsystems, Wetzlar, Germany). Cells with more than 5 strong nuclear γH2AX-foci were 
counted in 100 randomly selected transfected Rnaseh2b-/- MEFs [56]. For each patient or control, 
the number of fibroblasts harboring 0-3 nuclear DNA γH2AX-foci was determined in 50 randomly 
selected cells (nuclei with more than 3 stress foci were excluded) [23].  
 LN-229 cells transiently transfected with ADAR or RNASEH2B expression constructs and co-
transfected with pEGFP-C1 were fixed with 4% paraformaldehyde, permeabilized with 0.25% 
Triton X-100, stained with rabbit anti-IRF3 antibody (1:200 dilution, FL-425, Santa Cruz 
Biotechnology), and a Alexa Fluor 568-conjugated goat anti-rabbit IgG (1:500 dilution; A11011; 
Thermo Fisher Scientific). For each transfected sample, 200 GFP-positive cells were evaluated 
semi-quantitatively for their nuclear IRF3 expression level by taking into account the average 
staining intensity of each visual field and using the scores: no, weak, moderate, or strong.  
 The co-expression of IFNA6 and GFAP as well as CXCL10 and GFAP was assessed on 
FFPE glioma sections of patient III.3 of family 1 after heat-induced epitope retrieval in 10 mM 
citrate buffer pH 6.0, using rabbit anti-IFNA6 (1:100 dilution, HPA047557, Atlas Antibodies) or 
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rabbit anti-CXCL10 (1:100 dilution, bs-1502R, bioss Center for Biological Signalling Studies, 
University of Freiburg, Germany), and co-staining with mouse anti-GFAP (1:100 dilution, M0761, 
Dako, Glostrup, Denmark) as primary antibodies. As secondary antibodies, Alexa Fluor 568-
conjugated donkey anti-rabbit IgG (1:300 dilution, A10042, Thermo Fisher Scientific) and DyLight 
488-conjugated goat anti-mouse IgG (1:300 dilution, #35503, Thermo Fisher Scientific) were 
used. Cell nuclei were stained using Hoechst 33342 (Thermo Fisher Scientific). 
 
Assessment of calcification in tissue sections 
FFPE glioma and prostate carcinoma sections were hematoxylin eosin (HE) or von Kossa stained 
and evaluated for visible calcifications using the following score: 1, no detected calcification; 2, 
one small calcification; 3, several small calcifications; 4, several large calcifications.  
 
Expression analysis of IFNA6, CXCL10, and CD68 by immunohistochemistry  
The expression of IFNA6, CXCL10, and CD68 was assessed on FFPE glioma sections after 
heat-induced epitope retrieval in 10 mM citrate buffer pH 6.0, using rabbit anti-IFNA6 (1:100 
dilution, HPA047557, Atlas Antibodies), rabbit anti-CXCL10 (1:300 dilution, bs-1502R, bioss 
Center for Biological Signalling Studies, University of Freiburg, Germany), and mouse anti-CD68 
(1:200 dilution, M 0876, Dako) as primary antibodies. To improve CXCL10 staining, the antibody 
was diluted in Pierce immunostain enhancer (Thermo Fisher Scientific). As secondary antibody, 
horseradish-peroxidase-labeled goat anti-rabbit IgG (1:200 dilution, A24537, Thermo Fisher 
Scientific) was used. Sections were counterstained with hematoxylin (Gill No. 3, 1:10 dilution), 
scanned using the Aperio AT2 Scanner (Leica Microsystems), and digital images were processed 
using ImageScope v11.2.0.780 software (Leica Microsystems). On digital images of glioma 
sections from six patients with and five patients without rare ADAR or RNASEH2B variants, 
staining was assessed in six stained, non-overlapping, and non-necrotic areas per section using 
the following scoring system for staining intensity per area: 0.5, very weak; 1.0, weak; 1.5, 
moderate; 2.0, moderate to strong; 2.5, strong; 3.0, very strong, and mean staining intensity was 
calculated for each section.  
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Expression analysis of interferon stimulated genes (ISG) by real time RT-PCR  
The expression of six ISGs, found to be significantly upregulated in AGS patients [60], was 
assessed in whole blood of male patients III.2 and III.3 of family 1, female patient II.2 of family 2, 
and 20 controls (10 female and 10 male) matching the sex and age of the three family members. 
Total RNA was extracted using the PAXgene RNA isolation kit (PreAnalytix, Hombrechtikon, 
Switzerland). The expression of the three genes found to be upregulated in glioma patients 
(patients III.2 and III.3 of family 1, patient II.2 of family 2) here was assessed in transiently 
transfected LN-229 cells that had been treated with 1 µM Ruxolitinib in DMSO or DMSO control. 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen). cDNA was generated using the 
Superscript III First-Strand Synthesis System (Thermo Fisher Scientific). Relative quantification 
was performed using TaqMan Universal PCR Master Mix and TaqMan probes for IFI27 
(Hs01086370_m1), IFI44L (Hs00199115_m1), IFIT1 (Hs00356631_g1), ISG15 
(Hs00192713_m1), RSAD2 (Hs01057264_m1), and SIGLEC1 (Hs00988063_m1) (all Thermo 
Fisher Scientific). Target gene expression levels were normalized to the expression levels of 18S 
(Hs999999001_s1) and HPRT1 (Hs03929096_g1), and comparative Ct quantification was 
applied. Comparisons between expression levels of the six genes in the patient and the control 
group were calculated using two-tailed Student’s t test; multiple testing was corrected for using 
the Bonferroni-type False Discovery Rate procedure according to Benjamini and Hochberg [6]. 
 
Statistics  
Data are presented as mean ± SD. Statistical significance was calculated using two-tailed 
Student’s t test or Chi Square test, and statistically significant p-values are indicated.  
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Results 
Rare variants in the AGS genes ADAR and RNASEH2B are associated with glioma and 
prostate carcinoma risk and tumorigenesis  
In family 1, four individuals in three consecutive generations suffered either from IDH1-mutant 
anaplastic astrocytoma of WHO grade III (patients III.2 and III.3) or prostate carcinoma (patients 
I.1 and II.2). Whole blood derived DNA was available from the two brothers (patients III.2 and 
III.3) diagnosed with IDH1-mutant anaplastic astrocytoma at age 30 and 28 years, respectively, 
and from their father (patient II.2) affected by a prostate carcinoma (Fig. 1a), and WES was 
performed. First, to identify variants associated with glioma risk, germline variants shared by the 
two brothers were analyzed using an overlapping strategy (Supplementary Table 1). Of the 
shared high-quality variants, 108 were rare (MAF<1%), non-silent (i.e. non-synonymous 
missense, nonsense, frameshift, and splice site variants), and not found in 56 unrelated in-house 
controls. Of these variants, 28 fulfilled the following additional criteria: (i) predicted to be 
deleterious by at least one of four prediction tools, (ii) located within protein domains according to 
the Uniprot catalog, and (iii) affected genes harbored a second hit (single nucleotide or copy 
number variant) in the glioma DNA of patient III.3 based on WES data (Supplementary Table 2). 
A second filtering strategy was applied to the WES data, based on the hypothesis that the 
prostate carcinomas and the IDH1-mutant anaplastic astrocytomas in family 1 were part of a 
cancer syndrome caused by the same genetic variants. Therefore, germline variants shared by 
patients II.2, III.2, and III.3 were determined (Supplementary Table 3). Of the shared high-quality 
variants, 44 were rare (MAF<1%), non-silent (i.e. non-synonymous missense, nonsense, 
frameshift, and splice site variants), and not found in 56 unrelated in-house controls. Of these 
variants, nine fulfilled the following additional criteria: (i) predicted to be deleterious by at least 
one of four prediction tools, (ii) located within protein domains according to the Uniprot catalog, 
and (iii) affected genes harbored a second hit (single nucleotide or copy number variant) in the 
glioma DNA of patient III.3 based on WES data (Supplementary Table 4). Manual curation of the 
28 variants potentially associated with glioma risk (Supplementary Table 2), and the nine variants 
potentially associated with glioma/prostate carcinoma risk (Supplementary Table 4) by a clinical 
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geneticist (RGW) yielded two heterozygous variants in genes associated with the same rare 
autosomal recessive genetic disorder, AGS: ADAR,c.577C>G;p.(P193A), a mutation previously 
described in AGS patients [60], and RNASEH2B,c.495G>T;p.(K165N), a novel missense variant 
in the AGS gene RNASEH2B [17] (Supplementary Tables 9, 10). Verification and segregation 
analysis by Sanger sequencing in family 1 revealed that only the three family members affected 
by tumors and from whom DNA was available were simultaneously heterozygous for these ADAR 
and RNASEH2B variants, while three cancer-unaffected family members were not (Fig. 1a; 
Supplementary Fig. 1a). Through WES analysis of DNA derived from the IDH1-mutant anaplastic 
astrocytoma of patient III.3, second hits were detected in the ADAR and RNASEH2B genes, in 
addition to the germline missense variants, i.e. a 143 bp deletion partially affecting ADAR exon 3, 
a 286 bp deletion affecting ADAR exon 14, and a 225 bp deletion partially affecting RNASEH2B 
exon 1. Tumor DNA from the other two cancer-affected members of family 1 was not available for 
genetic analysis. 
 We then determined whether germline variants in ADAR and RNASEH2B occur at higher 
than normal frequencies in glioma patients with evidence for a genetic tumor predisposition, 
either because of multiple successive tumors in the glioma patient or cancer in family members, 
for whom we use the term familial glioma patients. Targeted sequencing of both genes on 
germline DNA of 59 additional familial glioma patients was performed. We detected that 
glioblastoma patient II.2 of family 2 was heterozygous for RNASEH2B,c.529G>A;p.(A177T) (Fig. 
1b; Supplementary Fig. 1b; Supplementary Tables 9, 10), a variant previously described in AGS 
patients [17], although the presence of two non-affected heterozygous mutation carriers in family 
2 indicates incomplete penetrance for a tumor phenotype (Fig. 1b; Supplementary Fig. 1b). 
However, the allele frequency for both of the AGS associated variants 
ADAR,c.577C>G;p.(P193A) and RNASEH2B,c.529G>A;p.(A177T) was 0.00833 (1 in 120 alleles) 
in familial glioma patients and, therefore, around 3 and 4 times higher than in non-Finnish 
Europeans from the ExAC data set [39], i.e. 0.00298 (199 in 66740 alleles) and 0.00193 (128 in 
66494 alleles), respectively, and both variants were not found in 263 in-house control exomes. In 
addition, a novel RNASEH2B variant was detected (Supplementary Table 9). Taken together, the 
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frequency of all rare (MAF<1%) non-silent deleterious RNASEH2B variants (that is, frameshift, 
stop gained/lost, canonical splice site, and initiation codon variants, as well as missense variants 
predicted to be deleterious by either SIFT or PolyPhen-2 prediction tools and not detected 
homozygously) in our unrelated familial glioma patients was significantly higher (2 families with 
multiple variant carriers in 60 families, 3.33%) than in (i) non-Finnish Europeans from the ExAC 
data set (243 variant carriers in 33,370 individuals, 0.73%) (two-tailed p-value=0.0181, Chi 
square test), and (ii) in-house control exomes (0 variant carriers in 263 individuals, 0%) (two-
tailed p-value=0.0340, Fisher’s exact test). No frequency comparison with control data sets was 
done for variation in ADAR because rare deleterious ADAR variants were not recurrently 
detected in our 60 familial glioma patients. No rare non-silent variants in ADAR or RNASEH2B 
were detected in the germline of 180 non-familial glioma patients, i.e. without multiple successive 
tumors or cancer in family members, including 130 patients affected by IDH1-mutant gliomas of 
WHO grade II or III, similar to patients III.2 and III.3 of family 1 found to be simultaneously 
heterozygous for ADAR and RNASEH2B variants (Supplementary Table 9). Because SNP 
rs498872 at 11q23 is one of the variants reported to specifically increase the risk for IDH1-mutant 
glioma [61], we assessed this variant on germline DNA from tumor-affected members of families 
1 and 2. While patient II.2 of family 1 diagnosed with prostate cancer was heterozygous for the 
risk allele (NM_015157.3:c.-199A>G), none of the patients affected by IDH1-mutant or IDH1-
wildtype gliomas carried the risk allele (Supplementary Fig. 2). Therefore, the risk allele at 11q23 
was not associated with the susceptibility for IDH1-mutant glioma in family 1. 
 Targeted ADAR and RNASEH2B sequencing was also performed on tumor-DNA from all 
three tumor types found in patients carrying rare ADAR or RNASEH2B germline variants, i.e. 
IDH1-mutant gliomas of WHO grade II/III, glioblastomas (on geographically distinct test and 
validation cohorts), and prostate carcinomas (on geographically distinct test and validation 
cohorts). While no rare non-silent somatic ADAR or RNASEH2B variants were found in 39 IDH1-
mutant gliomas of WHO grade II/III, the allele frequency for the known AGS variant 
RNASEH2B,c.529G>A;p.(A177T) was 0.025 (1 in 40 alleles), i.e. 13 times higher, in a 
glioblastoma test cohort, and that of ADAR,c.577C>G;p.(P193A) was 0.00893 (1 in 112 alleles), 
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i.e. 3 times higher, in a glioblastoma validation cohort compared to ExAC controls (0.00193 and 
0.00298, respectively). In addition, three novel and one rare ADAR variants not previously 
associated with AGS were identified in the glioblastoma test and validation cohorts 
(Supplementary Tables 9, 10). The variants ADAR,c.577C>G;p.(P193A) and 
RNASEH2B,c.529G>A;p.(A177T), detected in one glioblastoma each, were also found in non-
neoplastic tissue of the same patients (patient II.1 of family 3 and family 4), indicating that they 
were in fact germline alterations (Fig. 1c, d; Supplementary Fig. 1c, d). Furthermore, in addition to 
the RNASEH2B,c.529G>A;p.(A177T) variant in the glioblastoma of patient II.1 of family 4, the 
novel ADAR variant c.2891C>T;p.(A964V) was found, demonstrating that the tumor was 
simultaneously heterozygous for ADAR and RNASEH2B variants (Supplementary Table 10). 
Finally, we performed targeted sequencing of ADAR and RNASEH2B hot spot exons (see 
Materials and methods) in a test (n=15) and a validation cohort (n=50) of prostate carcinomas, to 
determine if our findings in glioblastoma also apply to prostate carcinoma. The allele frequency 
for ADAR,c.577C>G;p.(P193A) was 11 times higher in the prostate carcinoma test cohort 
(0.03333; 1 in 30 alleles) compared to ExAC controls (0.00298), whereas 
RNASEH2B,c.529G>A;p.(A177T) was 17 times higher in the test (0.03333; 1 in 30 alleles) and 5 
times higher in the validation (0.01000; 1 in 100 alleles) cohort compared to ExAC controls 
(0.00193). In addition, the novel RNASEH2B variant c.608A>G;p.(D203G) was detected in one 
patient in the validation cohort (Supplementary Tables 9, 10). Again, the AGS-associated variants 
ADAR,c.577C>G;p.(P193A) and RNASEH2B,c.529G>A;p.(A177T) were germline alterations as 
indicated by their presence in DNA from non-neoplastic lymph node from the same patients (Fig. 
1e; Supplementary Fig. 1e; Fig. 1f; Supplementary Fig. 1f). All gliomas harboring ADAR and/or 
RNASEH2B variants had no co-deletion of chromosomal arms 1p and 19q (Supplementary Table 
10), and were thus of astrocytic origin according to the current WHO classification of tumors of 
the central nervous system [40].  
 In summary, we detect novel variants and increased allele frequencies of certain rare 
variants in the AGS-associated genes ADAR and RNASEH2B in the germline and tumors of 
glioma and prostate carcinoma patients, suggesting an association of ADAR and RNASEH2B 
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alterations with glioma and prostate carcinoma risk and tumorigenesis, whereby germline variants 
in other genes may additionally contribute to tumor risk in these patients.  
 
The ADAR p.(P193A) variant destabilizes the protein-Z-DNA complex resulting in a partial 
unbinding of the Z-DNA, and affects tumor cell proliferation  
To gain insights into the effect of the ADAR p.(P193A) variant detected in the germline of glioma 
and prostate carcinoma patients at the molecular level, molecular dynamics simulations were 
carried out. Proline 193 is located in the Z-DNA/Z-RNA binding domain (designated Zα) of ADAR, 
and is part of a β-hairpin motif (β-wing) directly involved in Z-DNA interaction. P193 mainly 
contributes to Z-DNA binding through hydrophobic interactions [64]. Therefore by using molecular 
dynamics simulations, a comparison of the structure and conformational dynamics of the Zα 
domain in wildtype and mutant ADAR together with the bound Z-DNA could be made. As 
compared to wildtype ADAR, the p.(P193A) variant significantly increased the flexibility of the 
protein, leading to large structural fluctuation, in particular of Z-DNA binding elements, including 
helices α2 and α3, as well as the β-wing (β2 to β3) (Fig. 2a, b). Along the molecular dynamics 
simulation, these fluctuations disturbed the well-defined Z-DNA binding area and impaired shape 
complementarity resulting in an unbinding of the 3’ end of the Z-DNA and large conformational 
changes, thereby destabilizing the protein-Z-DNA complex (Fig. 2c, d). Next, we aimed to 
determine whether the ADAR p.(P193A) variant might facilitate tumorigenesis by affecting 
proliferation. Human LN-229 glioma and human HCT116 colorectal cancer cells stably 
expressing either wildtype interferon-induced ADAR p150 protein or the ADAR p.(P193A) variant 
were generated (Supplementary Fig. 3a), and growth kinetics were determined. While expression 
of wildtype ADAR caused a reduced proliferation of tumor cells as compared to vector control, 
expression of the ADAR p.(P193A) variant did not result in this growth suppressive effect 
(Supplementary Fig. 3b-g). Our findings provide in silico and in vitro evidence that the ADAR 
p.(P193A) variant may play a role in tumorigenesis by impairing Z-DNA interaction and enhancing 
cell proliferation. 
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Detected rare RNASEH2B variants cause increased double-strand DNA damage and impair 
ribonucleotide excision repair 
The RNase H2 complex is critical for the removal of ribonucleotides misincorporated into genomic 
DNA during replication and repair, and for the maintenance of genome integrity. MEFs from 
Rnaseh2b-/- mice display widespread genome instability, with γH2AX, a marker of DNA-damage 
response to double-strand breaks, substantially increased [56]. We explored the ability of 
wildtype versus mutant Rnaseh2b to rescue this DNA damage phenotype. Expression of the 
mutant murine proteins corresponding to the rare variants detected in glioma and prostate 
carcinoma patients, p.(K162N) and p.(A174T), in Rnaseh2b-/- MEFs (Supplementary Fig. 4) 
showed significantly reduced rescue from DNA damage compared to wildtype Rnaseh2b (Fig. 
3a). Comparable results were obtained in patient-derived human fibroblasts (Fig. 3b). In 
comparison to fibroblasts from four controls, cells from patient II.2 of family 2, carrying the 
RNASEH2B,c.529G>A;p.(A177T) alteration, were characterized by a significantly higher number 
of nuclear γH2AX foci (Fig. 3b). The observed DNA damage in RNase H2 deficient cells is 
generally thought to be the result of the impaired removal of misincorporated ribonucleotides. 
Consistent with this, we found that after expression of the Rnaseh2b p.(K162N) and p.(A174T) 
variants in Rnaseh2b-/- MEFs, isolated genomic DNA was more sensitive to RNase HII digestion 
as compared to Rnaseh2b-/- MEFs rescued with wildtype Rnaseh2b (Fig. 3c, d). This finding 
reflects a higher ribonucleotide content in the genomic DNA of Rnaseh2b-/- MEFs transfected with 
Rnaseh2b mutants versus wildtype Rnaseh2b. Our results suggest that the RNASEH2B germline 
variants identified in glioma and prostate carcinoma patients may promote tumorigenesis through 
increased double-strand DNA damage resulting from defective removal of genome-embedded 
ribonucleotides. 
 
Patients with rare ADAR or RNASEH2B mutations and their tumors recapitulate features of 
the AGS type I interferonopathy  
Cerebral atrophy and leukoencephalopathy were described in over 90% of children with AGS and 
commonly showed frontotemporal predominance [38]. Therefore, we evaluated tumor localization 
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and neuroradiological findings in glioma patients carrying rare ADAR or RNASEH2B germline 
variants. All four gliomas were located in the frontal or temporal lobe (Supplementary Table 10), 
and one of four patients showed bifrontal lobe atrophy (Fig. 4a). Brain calcification is another 
classical hallmark of AGS [2, 38]. Therefore, we assessed the presence of calcifications in 
gliomas or non-neoplastic brain of patients carrying rare ADAR or RNASEH2B variants. 
Calcifications were detected in the tumor or non-neoplastic brain of all four glioma patients with 
ADAR or RNASEH2B germline variants analyzed histologically, whereby these were numerous or 
large in two of the four cases (Supplementary Tables 10, 11; Fig. 4b, c; Supplementary Fig. 5a, 
b). Compared to five gliomas without ADAR or RNASEH2B variants, the six gliomas with ADAR 
or RNASEH2B variants showed an increased calcification score (Fig. 4d). Calcifications were 
also significantly more frequent in prostate carcinomas with versus without ADAR or RNASEH2B 
variants (Supplementary Fig. 5c-e; Supplementary Table 11).  
 To test whether type I IFNs are upregulated in ADAR or RNASEH2B variant-positive gliomas 
comparable to the findings in the CSF of AGS patients [62, 63], we determined the protein 
expression of interferon alpha 6 (IFNA6) by immunostaining of glioma sections. We observed that 
gliomas with ADAR or RNASEH2B variants showed a significantly higher IFNA6 expression in 
the cytoplasm of glial cells as compared to gliomas without ADAR or RNASEH2B variants (Fig. 
4e-h; Supplementary Fig. 6; Supplementary Table 11). Previously, it was reported that the type I 
IFN-inducible chemokine CXCL10 was elevated in the CSF and plasma of AGS patients [57, 62, 
63], and in skin lesions from patients with systemic lupus erythematosus (SLE) carrying 
heterozygous RNASEH2B variants [23]. Therefore, we performed CXCL10 immunostaining on 
tissue sections from gliomas with and without ADAR or RNASEH2B variants. Whereas ADAR or 
RNASEH2B variant-negative gliomas had a low mean CXCL10 score, gliomas with ADAR or 
RNASEH2B variants showed significantly enhanced CXCL10 expression in glial cells (Fig. 4i-l; 
Supplementary Fig. 6; Supplementary Table 11). Increased IFNA6 and CXCL10 expression was 
paralleled by a significantly higher CD68 expression in gliomas with versus without ADAR or 
RNASEH2B variants, consistent with an enhanced, IFNA6/CXCL10-induced recruitment of 
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macrophages and microglial cells into ADAR or RNASEH2B variant-positive tumors 
(Supplementary Fig. 7; Supplementary Table 11). 
 AGS has also been associated with increased expression of ISG transcripts in peripheral 
blood [15, 60]. Therefore, we assessed the expression of six genes significantly upregulated in 
AGS patients with biallelic ADAR mutations, i.e. IFI27, IFI44L, IFIT1, ISG15, RSAD2, SIGLEC1 
[60], in whole blood from three glioma patients carrying AGS-associated ADAR or RNASEH2B 
germline mutations. Transcript levels of IFI27, IFIT1, and RSAD2 were significantly increased in 
peripheral blood of these glioma patients as compared to twenty controls matching the patients in 
gender and age, while IFI44L, ISG15, and SIGLEC1 mRNA levels did not differ in glioma patients 
and controls (Fig. 4m; Supplementary Fig. 8).  
 Our findings indicate that the detected germline or somatic variants in both ADAR and 
RNASEH2B are associated with features of the AGS type I interferonopathy in glioma and 
prostate carcinoma tissue as well as in patients affected by these tumors. More specifically, our 
results provide in vivo evidence that these variants lead to upregulation of IFN as well as IFN-
induced genes, and suggest that they may contribute to tumorigenesis via enhanced interferon 
type I signaling.  
 
Enhanced ISG expression in vitro due to rare ADAR and RNASEH2B variants can be 
blocked by janus kinase (JAK) 1/2 inhibitor Ruxolitinib 
To confirm that the increase of ISG transcripts detected in the peripheral blood of glioma patients 
is due to ADAR and RNASEH2B variants, LN-229 cells were transiently transfected with wildtype 
or mutant ADAR or RNASEH2B constructs (Supplementary Fig. 9), and IFI27, IFIT1, and RSAD2 
mRNA levels were quantified. Expression of IFI27, IFIT1, and RSAD2 was significantly higher in 
tumor cells expressing ADAR p.(P193A) as well as RNASEH2B p.(K165N) and RNASEH2B 
p.(A177T) mutants as compared to wildtype ADAR or RNASEH2B, indicating an IFN type I 
response (Fig. 5a).  
 With the aim to identify therapeutic or prophylactic compounds for individuals carrying 
pathogenic ADAR or RNASEH2B variants, we used this cellular model to study signaling 
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pathways involved in ADAR and RNASEH2B mediated induction of ISG expression. It has been 
proposed that ADAR inactivation induces a type I IFN response and enhanced ISG expression 
via phosphorylation and subsequent nuclear translocation of transcription factor IRF3 [49]. 
Therefore, we compared nuclear IRF3 accumulation indicative of pIRF3 levels between LN-229 
cells expressing wildtype or mutant ADAR or RNASEH2B. Immunofluorescence revealed that a 
significantly higher percentage of cells had an elevated nuclear IRF3 score indicating increased 
levels of transcriptionally active IRF3 upon transient expression of mutant compared to wildtype 
ADAR and RNASEH2B (Fig. 5b, c; Supplementary Fig. 10). Our results suggest that the elevated 
ISG expression seen with mutant ADAR and RNASEH2B involves activation and nuclear 
translocation of IRF3. 
 Recently, constitutive epidermal growth factor receptor (EGFR) signaling was shown to 
activate IRF3 leading to increased expression of IFI27 and IFIT1 via the JAK/STAT1/2 pathway, 
which could be blocked by the JAK inhibitor Ruxolitinib in glioblastoma cell lines [10]. Therefore, 
we explored whether Ruxolitinib would have the same effect on high ISG expression induced by 
mutant ADAR or RNASEH2B in glioblastoma cells, in which we had shown IRF3 activation. We 
incubated LN-229 cells expressing wildtype or mutant ADAR or RNASEH2B with Ruxolitinib and 
expression of IFI27, IFIT1, and RSAD2 was quantified. Ruxolitinib treatment was found to 
abrogate the elevated ISG transcription levels seen for mutant ADAR and RNASEH2B (Fig. 5d). 
In summary, glioblastoma cells expressing mutant ADAR or RNASEH2B show a type I IFN 
response via activation of IRF3 that can be blocked by the JAK inhibitor Ruxolitinib, indicating 
that JAK/STAT signaling is involved. Our results suggest that glioma patients carrying germline 
mutations in ADAR or RNASEH2B might benefit from JAK inhibitors such as Ruxolitinib for the 
treatment of a glioma or prostate carcinoma or as an agent for tumor prevention.  
 
 
Discussion 
Here, we provide data suggesting that rare ADAR and RNASEH2B variants are associated with 
glioma and prostate carcinoma risk and tumorigenesis as well as a type I interferon signature. 
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The starting point of this study was family 1 with a clinically presumed susceptibility for glioma 
and prostate carcinoma because of four affected individuals in three consecutive generations. By 
whole-exome sequencing, three family members affected by IDH1-mutant anaplastic gliomas or 
prostate carcinoma were found to be simultaneously heterozygous for rare germline variants in 
ADAR and RNASEH2B, while three unaffected family members were not. Previously, 
homozygous or compound heterozygous mutations of ADAR and RNASEH2B have been 
reported to cause AGS [17, 60], whereby the ADAR c.577C>G;p.(P193A) variant detected here in 
German cancer family 1 and found to be enriched 3- to 11-fold in the germline and tumor DNA of 
glioblastoma and prostate carcinoma test and/or validation cohorts as compared to ExAC 
controls, was described in five AGS families of European ancestry [60]. This alteration lies in the 
Zα domain of the adenosine deaminase, which specifically recognizes DNA and RNA in a higher 
energy Z-conformation, and only affects the IFN-inducible p150 isoform of ADAR. Here, 
molecular dynamics simulations indicate an increased structural flexibility of the ADAR Zα domain 
due to the p.(P193A) variant, which significantly affected the Z-DNA/Z-RNA binding area, 
impairing Z-DNA interaction and destabilizing the protein-Z-DNA complex. Our findings are 
consistent with previous results that binding of Z-DNA to the ADAR Zα domain is shape-specific 
[24, 29, 64]. Moreover, our simulations may have identified the structural basis underlying both 
the altered RNA editing activity described previously [44] and the impaired growth suppression of 
the ADAR p.(P193A) variant shown here, as compared to the growth suppressive effect of 
wildtype ADAR reported here and previously [50]. Both effects may be linked since changes of 
RNA editing levels may be a general mechanism to promote tumor growth [66]. Furthermore, 
localization of the ADAR p.(P193A) variant to cytoplasmic stress granules, which requires a 
functional Zα domain [47], may be impaired.  
 In addition to the novel RNASEH2B variant in family 1, we detected the RNASEH2B 
c.529G>A;p.(A177T) alteration, previously reported in 14 of 18 AGS families of European or 
North-African descent [17], in the glioblastoma patient of German cancer family 2 resulting in a 
significantly higher frequency of rare deleterious RNASEH2B variants in the germline of familial 
glioma patients than in ExAC controls. As shown in Rnaseh2b-/- MEFs, both Rnaseh2b variants 
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impact on ribonucleotide excision repair and DNA damage. Additionally, fibroblasts from our 
glioblastoma patient carrying the RNASEH2B c.529G>A;p.(A177T) alteration showed signs of 
chronic low-level DNA damage, as described previously for fibroblasts with a heterozygous 
RNASEH2B mutation from an SLE patient [23]. That report demonstrates a significant 
contribution of rare variants of the RNASEH2 genes, RNASEH2A, RNASEH2B, and RNASEH2C, 
to SLE risk [23]. Taken together, the study by Günther et al. and our report extend the phenotypic 
spectrum caused by ADAR and RNASEH2B genetic variation beyond AGS to SLE and glioma 
and prostate carcinoma risk. This link is not unexpected because SLE patients have an overall 
increased risk of malignancy compared with the general population [22]. A direct association 
between AGS genes and other cancer types was suggested by two recent studies [14, 51]. 
Clifford and colleagues reported on a homozygous germline SAMHD1 mutation in an AGS patient 
who developed CLL at 24 years of age, and acquired SAMHD1 mutations in around 10% of 
relapsed/refractory CLL patients [14]. Studying over 10,000 cases and over 20,000 controls, 
Permuth and colleagues found a significant association between genetic variation in ADAR and 
epithelial ovarian cancer susceptibility [51]. 
 Our study provides evidence that rare variants in both AGS genes found altered here, ADAR 
and RNASEH2B, are associated with features of the AGS type I interferonopathy in tumors and 
tumor patients, whereby the patients were not affected by the full spectrum of AGS symptoms 
because they were heterozygous or simultaneously heterozygous mutation carriers. First, seven 
of eight gliomas with an ADAR or RNASEH2B variant were located in the frontotemporal brain, 
where AGS associated leukoencephalopathy is predominant [38]. Second, calcification, an AGS 
hallmark usually occurring in the brain [2, 38], was more likely in gliomas and significantly more 
pronounced in prostate carcinomas with ADAR or RNASEH2B variants than without. Third, 
expression of IFNA and of type I IFN-inducible CXCL10, produced by astrocytes in AGS [63], was 
elevated in gliomas with ADAR and RNASEH2B variants compared to ADAR and RNASEH2B 
wildtype gliomas. Similarly, high CXCL10 expression was previously observed in lesional skin 
from an SLE patient carrying a heterozygous RNASEH2B variant [23]. Fourth, similar to AGS 
patients and their heterozygous parents [15, 60], increased expression of a subset of ISG 
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transcripts (IFI27, IFIT1 and RSAD2) was found in peripheral blood of glioma patients carrying 
germline ADAR and/or RNASEH2B variants.  
 The link between ADAR and RNASEH2B variants and enhanced expression of certain ISGs 
was corroborated by our finding that elevated levels of IFI27, IFIT1 and RSAD2 could also be 
induced in vitro by expressing ADAR and RNASEH2B variants in tumor cells. Using this cellular 
model, we found that stimulation of ISG expression by ADAR and RNASEH2B variants is 
mediated by activation of the transcription factor IRF3, known to play a key role in antiviral innate 
immunity. It was recently shown that IRF3 is also activated by constitutive EGFR signaling 
leading to expression of IFI27 and IFIT1 in glioblastomas [10]. Aberrant EGFR signaling caused 
by EGFR amplification and/or constitutively activating mutation is common in human tumors 
including malignant astrocytic gliomas and prostate carcinomas [3, 11], and enhances 
tumorigenicity [33]. Here, we propose that germline or somatic ADAR and RNASEH2B variants 
result in the same downstream signals as constitutively active EGFR, thus representing an 
alternative mechanism for tumorigenesis in certain cancers such as gliomas and prostate 
carcinomas, whereby tumor initiation is enhanced by ADAR and RNASEH2B germline variants as 
opposed to malignant progression by somatic deregulation of EGFR signaling. IFN pathway 
activation by constitutive EGFR signaling via IRF3 was abolished by JAK inhibitor Ruxolitinib [10], 
as might be expected because IRF3 activates the JAK-STAT pathway by stimulating IFN-β 
transcription leading to the transcription of ISGs. Here, we show that Ruxolitinib also suppresses 
ADAR and RNASEH2B variant-mediated expression of the ISGs IFI27 and IFIT1. Thus, targeting 
the JAK-STAT pathway by inhibitors may have prophylactic or therapeutic potential in individuals 
carrying pathogenic ADAR and RNASEH2B variants regarding the tumor phenotype. Previous 
studies have indicated that the JAK2 inhibitor AZD1480 suppresses the growth of human 
xenografts from prostate cancer cells [28], and from glioma cells thus increasing the survival of 
mice bearing intracranial glioblastoma xenografts [45], supporting the development of JAK 
inhibitors for the treatment and possibly the prevention of solid tumors in individuals with ADAR 
and RNASEH2B variants.  
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 We propose that rare ADAR and RNASEH2B germline variants specifically increase the risk 
for diffusely infiltrating gliomas without co-deletion of chromosomal arms 1p and 19q, which may, 
however, carry IDH1 mutations or not. According to the current WHO classification of tumors of 
the central nervous system, diffuse gliomas without 1p/19q deletion are astrocytic tumors [40]. 
Furthermore, the IDH mutation status is a major classification parameter for gliomas [40]. Our 
data suggest that in the brain, rare ADAR and RNASEH2B germline variants lead to astrocytic 
tumors only, which may then acquire IDH1 mutations or not. From a transgenic mouse with CNS 
expression of IFNA, we know that the neuropathologic changes include astrocyte hypertrophy, 
progressive calcification, and up-regulation of a number of IFNA-regulated genes [8], mimicking 
the findings in the diffuse astrocytic tumors with rare ADAR and RNASEH2B variants described 
here. Therefore, the type I interferonopathy in patients carrying rare ADAR and RNASEH2B 
germline variants may specifically impact astrocytes or astroglial progenitors in the brain, thereby 
increasing the risk for the development of astrocytic gliomas. Recently, astrocytes were shown to 
produce IFNA as a paracrine signal that supports metastatic tumor growth, providing evidence for 
an association between inflammatory cytokines, such as IFNA, and growth of brain metastatic 
cells [12]. Mediated by dsDNA, metastatic cancer cells triggered astrocyte cytokine release via 
cGAS by transferring cGAMP through gap junctions into neighboring astrocytes, where IRF3 was 
activated via STING [12]. A role for the IFN stimulator STING in the control of cancer was shown 
in STING-/- mice, which were largely resistant to skin carcinogenesis induced by a mutagen 
causing accumulation of nuclear DNA in the cytosol, a trigger leading to intrinsic cytokine 
production and tumor development in a STING wildtype setting [1]. The cGAS/STING nucleic 
acid-sensing pathway is also relevant to AGS as reported in the Rnaseh2bG37S/G37S and the 
Rnaseh2bA174T/A174T knock-in mice [42, 53]. Therefore, data from this and other studies provide 
direct and indirect evidence for an association between AGS-related gene mutations and type I 
IFN-induced tumorigenesis, whereas the study of cancer risk in patients with AGS is hampered 
by the fact that the severe neurological dysfunction often causes lethality in childhood, with only 
around 2% of patients still alive at more than 30 years of age [15].  
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 IDH1 is another gene, in which an association between somatic mutation, inflammation, and 
glioma tumorigenesis is proposed, whereby the starting point is the formation of the 
oncometabolite 2-hydroxyglutarate leading to over-excitation of NMDA receptors, increased IL-1β 
production, and IL-6 induction via the JAK/STAT pathway [46]. In the gliomas with somatic IDH1 
mutations of our study, the germline ADAR and/or RNASEH2B variants will have preceded this 
mutation, while in the tumor cells variation in all three genes may additively promote inflammation 
and drive tumor progression. However, since IDH1 mutations were not detected in most gliomas 
with ADAR and/or RNASEH2B variants described here, ADAR and RNASEH2B variants may 
represent genetic equivalents of IDH1 mutations in inducing inflammation-driven malignant 
transformation. 
 In summary, our results link ADAR and RNASEH2B, previously associated with the 
inflammatory disease AGS and the autoimmune disorder SLE, and an enhanced type I IFN 
response to glioma and prostate carcinoma risk and tumorigenesis. Furthermore, we propose 
that targeting the type I IFN signaling axis by inhibitors may have prophylactic or therapeutic 
potential regarding a tumor phenotype in individuals carrying pathogenic ADAR and RNASEH2B 
variants. 
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Figure legends 
Fig. 1 Germline alterations in the AGS genes ADAR and RNASEH2B in families with glioma and 
prostate cancer. a Pedigree of family 1 and segregation of ADAR and RNASEH2B germline 
alterations detected by WES. Patients III.2 and III.3 each diagnosed with IDH1-mutant anaplastic 
astrocytoma of WHO grade III and their father II.2 affected by a prostate carcinoma are 
simultaneously heterozygous for rare variants in ADAR and RNASEH2B. The ADAR variant is a 
known AGS mutation, while the RNASEH2B variant is novel. All tested family members carrying 
both variants were affected by cancer. The paternal great-uncle who died from prostate 
carcinoma, and the grandmother who died from an adrenal tumor were unavailable for genetic 
testing. M1: ADAR,c.577C>G;p.(P193A), M2: RNASEH2B,c.495G>T;p.(K165N). Asterisks 
indicate patients in whom WES analysis was performed. b Pedigree of family 2 and segregation 
of the germline RNASEH2B,c.529G>A;p.(A177T) (M3) variant, a known AGS mutation. Patient 
II.2 affected by a glioblastoma of WHO grade IV carried the RNASEH2B mutation, while a 
mutation carrier’s son diagnosed with myelodysplastic syndrome was unavailable for genetic 
testing. c-f ADAR,c.577C>G;p.(P193A) (M1) and RNASEH2B,c.529G>A;p.(A177T) (M3), two 
known AGS mutations, were also detected in the germline (non-neoplastic tissue) and tumor of 
glioblastoma patients in families 3 and 4 as well as in the germline (non-neoplastic tissue) and 
tumor of prostate carcinoma patients in families 5 and 6. Question marks indicate that it is 
unknown whether an individual was affected by a tumor or not. 
 
Fig. 2 Structural changes in the Zα domain of ADAR P193A variant compared to wildtype (WT) 
protein detected during molecular dynamics (MD) simulations destabilize Z-DNA binding. a The 
ADAR P193A missense variant in the β-wing leads to an increased structural flexibility of the 
protein, in particular of the Z-DNA/Z-RNA binding β-wing, during MD simulations (indicated by 
brownish vectors on the Cα atoms). The starting structure of the ADAR Zα domain is shown as 
green colored cartoon representation, the maximal displacement of the structure along the MD 
trajectory as transparent cartoon, and the bound Z-DNA as wheat colored cartoon representation. 
The duplex ADAR Zα domain and Z-DNA, which were part of the simulation system, are 
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displayed as white silhouette (not shown in c and d). b Difference root mean square fluctuation 
(RMSF) diagram (WT – P193A) averaged over the amino acid residues, showing the increased 
fluctuations of the P193A variant as compared to wildtype. c Snapshots of the wildtype ADAR MD 
trajectory. The Z-DNA binding area remains stable and well-pronounced over the simulation time. 
Only minor changes are detectable in the protein and Z-DNA along the trajectory. d Snapshots of 
the ADAR P193A variant simulation. Larger conformational changes occur in the Zα domain, 
which appear to destabilize Z-DNA binding. Note the marked conformational changes of the Z-
DNA. The Zα domain is shown as a green surface with the position of P193 highlighted in gold, 
and the Z-DNA as a wheat colored cartoon representation (c and d). 
 
Fig. 3 RNASEH2B mutant proteins increase double-strand DNA damage and impair 
ribonucleotide removal from genomic DNA. a Rnaseh2b-/- MEFs transiently transfected with 
constructs expressing Rnaseh2b (Rh2b) p.(K162N) or p.(A174T) mutants showed a reduced 
DNA damage rescue, i.e. a significantly higher percentage of Rnaseh2b-/- MEFs with more than 
five γH2AX DNA damage foci was observed, than after wildtype Rnaseh2b re-expression (mean 
± SD for n=4 independent experiments). b In human fibroblasts from patient II.2 of family 2 
carrying the RNASEH2B,c.529G>A;p.(A177T) variant, significantly more nuclei harbored 1-3 
γH2AX foci as compared to four control fibroblast cell lines, indicating increased double-strand 
DNA damage (mean ± SD for n=3 independent experiments). Representative images of stained 
fibroblast nuclei are shown. c Genomic DNA from Rnaseh2b+/+ MEFs, Rnaseh2b+/- MEFs and 
transiently transfected Rnaseh2b-/- MEFs was analyzed on an alkaline agarose gel to estimate 
sensitivity to recombinant RNase HII enzyme as a measure of ribonucleotide excision repair and 
DNA integrity. d Densitometric evaluation of high molecular weight genomic DNA bands from (c) 
revealed a decreased rescue of Rnaseh2b-/- genomic RNase HII mediated DNA fragmentation 
reflecting a higher ribonucleotide content when expressing Rnaseh2b mutants versus wildtype 
(mean ± SD for n=3 independent experiments). *, p < 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 (Student’s t 
test). 
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Fig. 4 Glioma patients with rare ADAR or RNASEH2B variants and their tumors recapitulate 
features of the AGS type I interferonopathy. (a-d) Glioma patients with rare ADAR or RNASEH2B 
variants show hallmark pathologic brain features of AGS patients. White matter hyperintensity on 
T2-weighted magnetic resonance imaging of patient II.2 of family 2 indicates 
leukoencephalopathy, and the widened sulci indicate bifrontal lobe atrophy (asterisks) (a). HE 
stained tissue sections reveal several large calcifications (arrows) in the glioma of patient III.2 of 
family 1 (b; scale bar: 300µm), and one small calcification in the non-neoplastic brain tissue of 
patient II.2 of family 2 (c; scale bar: 60µm). Tumor or brain calcifications of other patients are 
summarized in Supplementary Tables 10, 11, and shown in Supplementary Fig. 5. The 
calcification score was elevated in gliomas with (n=6) versus without (n=5) rare ADAR or 
RNASEH2B variants (mean ± SD) (d). e-h IFNA6 immunoreactivity in a representative glioma 
without ADAR or RNASEH2B variants (e: tumor Gb6) and two representative gliomas with ADAR 
or RNASEH2B variants (f: tumor Gb9; g: glioma from patient III.2 of family 1); scale bar: 60µm. 
The IFNA6 expression was significantly higher in gliomas with (n=6) versus without (n=5) ADAR 
or RNASEH2B variants (mean ± SD) (h). i-l Immunostaining of type I IFN-inducible CXCL10 in a 
representative glioma without ADAR or RNASEH2B variants (i: tumor Gb19) and two 
representative gliomas with ADAR or RNASEH2B variants (j: glioma from patient III.3 of family 1; 
k: tumor Gb16); scale bar: 60µm. Gliomas with ADAR or RNASEH2B variants (n=6) showed 
significantly higher CXCL10 scores as compared to gliomas without ADAR or RNASEH2B 
variants (n=5) (mean ± SD) (l). m Glioma patients with rare ADAR or RNASEH2B variants (filled 
black symbols; n=3) show significantly increased transcript levels of ISGs IFI27 (circles), IFIT1 
(squares) and RSAD2 (triangles) in whole blood normalized to 18S expression levels versus 
controls (unfilled symbols; n=20). Scatter plots show RQ values on a log10-scale for each 
individual (mean for n=2 independent experiments performed in triplicate, red lines indicate the 
mean value of each group). Given are significance levels calculated using two-tailed Student’s t 
test. The expression differences between patients and controls remain significant after correcting 
for multiple testing [6]. WT, wildtype ADAR and RNASEH2B; mut, mutant ADAR and/or 
RNASEH2B; pts, patients; *, p < 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 (Student’s t test). 
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Fig. 5 ISG expression induced by ADAR and RNASEH2B variants via IRF3 activation is 
suppressed by JAK1/2 inhibitor Ruxolitinib. a Transcript levels of ISGs IFI27, IFIT1, and RSAD2 
were significantly enhanced upon ADAR p.(P193A) mutant versus wildtype ADAR, and 
RNASEH2B p.(K165N) and p.(A177T) mutants versus wildtype RNASEH2B expression in LN-
229 cells (mean ± SD for n=3 independent experiments performed in triplicate). b Nuclear IRF3 
accumulation was detected in a significantly higher percentage of LN-229 cells upon expression 
of ADAR and RNASEH2B mutants as compared to wildtype ADAR and RNASEH2B by 
immunofluorescence (mean ± SD for n=3 independent experiments). c Images show the 
inhibiting effect of wildtype ADAR on nuclear IRF3 accumulation that is not detected upon 
expression of ADAR p.(P193A) mutant (more images are shown in Supplementary Fig. 10). d 
Treatment with 1 µM JAK1/2 inhibitor Ruxolitinib versus DMSO control abolished induction of 
IFI27, IFIT1, and RSAD2 transcript levels upon expression of mutant ADAR and RNASEH2B in 
LN-229 cells (mean ± SD for n=3 independent experiments performed in duplicate). *, p < 0.05; 
**, p ≤ 0.01; ***, p ≤ 0.001 (Student’s t test). 
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